Skystar Bio-Pharmaceutical Company
Skystar Bio-Pharmaceutical — Roth Capital Conference 2007
44 slides from Skystar Bio-Pharmaceutical's conference presentation, Sep 5, 2007

Slide 1: Roth Capital Conference
- Roth Capital Conference September 2007 Scott Cramer, Director, Skystar Bio- Pharmaceutical

Slide 2: Forward-looking statements
Statements in this presentation may be "forward-looking statements’ within the meaning of federal securities laws. The matters discussed herein that are forward-looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations n

Slide 3: Skystar company snapshot
‘SKYSTAR, Listed on the OTC BB SKBI FY Ends Dec 31st Price on 08/30/2007 $1.20 52-Week High/Low $2.60/ $0.95 Revenues (ttm) $10.8M Net Income (ttm)* $2.0M Market Capitalization $21.0M Diluted Shares Outstanding (06/30/07) 17.5M 2007 Est. Revenue $12-14M 2007 Est. Non-GAAP Net income $2.5-3M 2007 Est

Slide 4: Modernization of meat processing drives growth in China's veterinary industry
~ Modernization of meat processing drives double-digit growth in China’s $1.8 billion veterinary industry ~ Newly regulated industry in China with no market leader ~ Extensive product line covering all key segments of animal farming industry

Slide 5: Rapidly growing high margin veterinary line
~ Rapidly growing high margin veterinary line w Expanded production capacity by 200% to meet demand ~» Proven track record of strong financial growth

Slide 6: China-based producer and distributor of veterinary medicines
China-based producer and distributor of — veterinary medicines, vaccines, microorganisms and feed additives ~ Over 100 products in portfolio ~» Over 50 products under development ~ Strategic sales and distribution network of 500 distribution agents covering 27 provinces

Slide 7: Skystar company profile
'SKYSTAR China-based producer and distributor of veterinary medicines, vaccines, microorganisms and feed additives ~ Good Manufacturing Practice (GMP) compliant production facilities and processes ~ Headquartered in Xi’an, Shaanxi Province, China ~ 230 employees with 210 full time (as of 08/30/2007)

Slide 8: Modernization of Livestock Industry
Modernization of Livestock Industry — Supports Increasing Demand — ye, ~China is the largest producer of — poultry and livestock in the world with total output exceeding $172.9 billion in 2005* wlindustry evolving from single farmer to large-scale meat processing plants ‘National Bureau of Statistic

Slide 9: Government supports rapid development of modernization
'SKYSTAR ~~ Government supports rapid development of modernization @ Improve overall production and quality to meet international standards o Must adhere to Good Manufacturing Practices $200) Animal Husbandry Output in China ($B)* so : - 4980 1989 1991 1993 1995 1997 1999 2001 2003 2005 “National Bu

Slide 10: Total 2006 output of meat and poultry
» Total 2006 output of a o@ Meat and poultry estimated at 81 million tons, up 5% from 2005* @ Eggs estimated at 29.5 million tons, up 3% from 2005* 90 Output of Meat in China 80 (Millions tons)* o ° 70 o” ° ° ° 60 o* 50 ‘ ° 40 + © SS & Se 2 PST PL LM? LM? L PPP HF SF FS lise F SF ‘National Bureau of

Slide 11: $1.8 billion market for veterinary medicine
+ $1.8 billion market for veterinary medicine and pharmaceuticals in China growing 24% annually* wHigher living standards spur demand for animal-based food sources "OECD Economie Survey of China 2005 and China Annual Book of Statistics 2005 * Chinese Goverment Official Web Portal

Slide 12: Disease prevention
~» Disease prevention e Animal diseases such as the Avian Flu and blue-ear disease in China cost $5.18 billion annually** °Flu Prevention estimated at $0.7~1.2 billion in 2005* e Parasitic diseases prevention estimated at $125* million in 2005 ~ Growing pet ownership "OECD Economie Survey of China 2

Slide 13: Vibrant Aquaculture Industry
ibrant Aquaculture Industryzm% ae ~ Aquaculture production in China was 33.6 million tons in 2005* ~ China contributes to 70% of the worlds aquaculture ~ China is only country in the world with aquaculture greater than wild catch “Food and Agricul ation of the United Nations

Slide 14: Vibrant Aquaculture Industry
ibrant Aquaculture Industry pam ‘SKYSTAR ~ Aquaculture expected to increase as China is restraining offshore fishing until 2010 ~ Aqua feed estimated at 13.4 million tons in 2007 “Food and Agriculture Organization ofthe United Nations

Slide 15: Largest competitors: State Owned Enterprises
~Largest competitors: State Owned Enterprises ~ Majority of over 2,600 competitors with GMP certification only offer 1-2 drugs ~ High barriers for international competitors

Slide 16: Skystar's competitive advantages
~Skystar’s competitive advantages Building leadership position aExtensive portfolio ae aNational brand aDistribution network aEstablishing 300 franchise stores in 2007 Only U.S. listed veterinary supply company in China

Slide 17: Broad portfolio of products covering all areas of animal health care
~» Broad portfolio of products covering all areas of animal health care 2Q 2007 % Revenue by Product Line 5.0% 39.0% 11.0% © Veterinary medications ll Feed additives, | Microorganisms © Vaccines

Slide 18: Veterinary medicines
‘SKYSTAR ~ Over 80 veterinary medicines in the form of powder, injection and tablets for poultry, livestock and pets ~ Received approval for 52 new drugs this year from Ministry of Agriculture e Expect to receive approval for 48 additional drugs by year end ¢ Average gross margin for new drugs expec

Slide 19: Microorganisms products
‘SKYSTAR ~» Over 10 microorganisms products to cure and prevent livestock diseases ~ Developed over 20 new microorganism products with drug-resistant lactobacillus acidophilus ~ Recently began producing microbial strains in-house o Key ingredient for microorganisms & feed additives @ Reduces product

Slide 20: Vaccine products
'SKYSTAR ~» Over 10 vaccine products that cover both active vaccines and inactive vaccines ~» Top vaccine product: DLV Avian Coccidiosis vaccine ~» New workshop for research and development of vaccines to be completed by the end of 2007 Wem ii

Slide 21: Feed additives
$40 billion market in 2006* ~¥12 feed additive products in a few series such as multi-enzyme amine and sodium diacetate ~Optimize production yield and health of livestock

Slide 22: Expanding Products & Capacity
__ Expanding Products & Capacity pané ‘SKYSTAR ~» New GMP certified plant increases capacity by 200% 2 Six billion doses of vaccines 26,250 metric tons of microorganisms / probiotics feed additives

Slide 23: Expanding Products & Capacity
Expanding Products & Capacity rs || y ~» New GMP certified plant increases capacity by 200% 250 million doses of medicines in liquid form 2200 million veterinary tablets 23,000 metric tons of powder form of veterinary medication

Slide 24: Strategic partnerships
‘SKYSTAR » Strategic partnerships @ Shanghai Institute of Animal Parasitology of The Chinese Academy of Agricultural Sciences oe Jiangsu Microorganism Institute @ Shaanxi Microbial Institute

Slide 25: R&D Projects
-_ —_—_ Oo R&D Projects ‘SKYSTAR, ~» Specialized vaccines and veterinary medicines to prevent Avian Influenza (H5N1) infection in birds ~ Products to stimulate the release of growth hormones in piglets ~ New feed additives based on protein technology and complex enzyme preparations ~ Over 20 product

Slide 26: Products targeting PRRS (blue ear disease)
‘SKYSTAR Launched several products targeting porcine reproductive and respiratory syndrome (PRRS), aka blue ear disease April, 2007 launched Chinese Goldthread (Huanglian) Detoxification Powder ("CGDP") eTests demonstrate effectiveness in treating PRRS =

Slide 27: Rapidly Respond to Market Demand
‘a Rapidly Respond to Market De ‘SKYSTAR, Launched several products targeting porcine reproductive and respiratory syndrome (PRRS), aka blue ear disease July, 2007 launched First Aid Kit for Swine High Fever Syndrome o Cures the complications caused by blue ear disease 2 Sold over 3,000 kits to date

Slide 28: Branch companies and franchise chain stores
‘SKYSTAR, » Open four major branch companies to cover all of China ~» Open more than 300 Skystar franchise chain stores in 2007 ~» Doubled number of distributors to over 500 + Commitment to after sales support —

Slide 29: Expanded advertising and marketing
increase print media through expanding advertising from two magazine/newspapers to six ~Produce and run more commercials on local TV channels wOrganize local seminars, a popular source of information in rural areas ~ Attend more nationwide industry conferences EE

Slide 30: Weibing Lu, Chairman and CEO
Weibing Lu, Chairman and CEO e@ Founded Xian Tianxing in 1997 2 BS from Wuhan University in 1985 and MBA from Xi'an University in 1999. e Awarded Outstanding Entrepreneur of Xi'an Feed Industry in 2002 e Appointed as a Director of Xi'an Institute of Feed Industry

Slide 31: Wei Wen, Director and Vice General Manager
‘SKYSTAR, Wei Wen, Director and Vice General Manager e Secretary of the Board and Vice GM since founding of Xian Tianxing. e@ Graduated from Xi’ an University of Science and Industry in 1986 @ Manager and Vice GM at the Sales Department of two companies from 1990 to 1997

Slide 32: Xinya Zhang, Director and Vice GM
Xinya Zhang, Director and Vice GM @ Vice GM since founding of Xian Tianxing °@ Graduated from Northwest Agricultural University in Shaanxi Prov. 2 Factory Director and General Engineer of Xi'an Hua’an Livestock Group Co. Feed Factory from 1990 to 1997

Slide 33: Annual revenues
SS $9.8 $4.0 pa $4.7 ) on 8 mm : : , 2003 2004 2005 2006 6Mos 2007E 2007 (Revenues in $M)

Slide 34: Quarterly revenues
$3.6 $3.4 $2.8 $2.5 $1.4 $1.0 7 1Q06 2Q06 3Q06 4Q06 1Q07 2Q07 (Revenues in $M)

Slide 35: Gross profit and gross margin
2003 2004 2005 2006 6 Mos 2007 @5 Gross profit ($M) —*— Gross margin ‘SKYSTAR, 0%

Slide 36: Net income and profit margin
2003 2004 2005 2006* 6Mos 2007E 2007** 3 Net income ($M) —*— Profit margin “Non-GAAP excluding amorizaton of defered compensation of $12 millon “Non-GAAP excidig amortzaton of defered compensation of $380 299 and non cash ‘expense relate to amortzaton of corverble debenture and warrants of S728, 224

Slide 37: Quarterly net income and profit margin
‘SKYSTAR, $1.0 25% * 22.8% ns 20% 15% $0.5 10% $0.2 $0.1 5% $0.0 + ml Lal + 0% 1006 2006 3006 4q06" 1007" 207 BE Net income ($M) —* Profit margin + Non-GAAP excusing anortizaton of deterred compensation of $545 013 "Non-GAAP excluding amortzatton of deemed conpersaton of $30,869 and non cash expense

Slide 38: Balance sheet summary
Cash and Cash Equivalents 2,900 Total Current Assets 5,226 Total Assets 17,801 Total Current Liabilities 1,287 Working Capital 3,939 Debt/ Equity 19 Total Stockholders’ Equity 14,989

Slide 39: Adjusted net income
‘SKYSTAR Adjusted Net income Qt 2007 2 2007 Six Months 2007 Net Diluted Net Diluted += Net '—illuted Net Income (Loss) Diluted EPS Income EPS Income EPS Income _ EPS. Adjusted Amount 122,975 771,044 533,116 ‘Adjustments Deferred Debenture Expense (1) 40,876 00 | 122,628 0.007 | 163,504 0.01 Discount

Slide 40: Equity Capital Table
_ EE _4 Equity Capital Table SoH res |! ‘SKYSTAR Basic shares outstanding 12,795,549 Preferred stock 2,000,000 Common stock underlying convertible debentures 4,727,000 Warrants to purchase common stock (exercise price: $1.20) 4,075,000 Placement agent warrants (exercise price: $1.00) 570,500 Total 1

Slide 41: Peer comparison
Ticker Stock Symbol Price Company Skystar SKBI $1.20 21.0M $0.14" Heska Corp. HSKA $2.09 107.2M $0.10 MWI Veterinary Supply MWIV $37.59 451.6M $1.33 Neogen Corp. NEOG $31.83 207.9M 0.97 Immucel Corp. Iccc $3.66 106M 0.19 VCA Antech Inc. WOOF $40.14 348 1.30 As of Aug 30, 2007, all data from Reuters

Slide 42: Establishing leading position in veterinary care market
‘SKYSTAR, ~ Establishing leading position in rapidly growing veterinary care market ~ Building extensive portfolio of high margin products ~lncreased capacity 200% to meet growing demand

Slide 43: R&D, distribution and management strengths
~ Strong research & development initiatives improve product quality and animal health ~ Expanding sales and distribution network ~ Experienced management team

Slide 44: Skystar Bio-Pharmaceutical Company contact
Skystar Bio-Pharmaceutical Company Scott Cramer, Director - U.S. Representative Phone: 407-645-4433 Email:[email protected] CCG Elite Investor Relations Leslie Richardson Phone: 310-231-8600 x 122 [email protected]
Source: SEC EDGAR · 8-K filed Sep 5, 2007
More decks from Skystar Bio-Pharmaceutical Company
RENN Investor Conference, May 14, 201037 slides · May 17, 2010
Investor Presentation (March 2010)41 slides · Mar 17, 2010
Investor Presentation (March 2010)34 slides · Mar 8, 2010
Investor Presentation (November 2009)40 slides · Nov 20, 2009
Investor Presentation (October 2009)30 slides · Oct 14, 2009
Investor Presentation (September 2009)43 slides · Sep 9, 2009